Diagnostic and prognostic value of the new tumour marker CYFRA 21-1 in patients with squamous cell lung cancer.

@article{Nikliski1995DiagnosticAP,
  title={Diagnostic and prognostic value of the new tumour marker CYFRA 21-1 in patients with squamous cell lung cancer.},
  author={Jacek Nikliński and Mark Furman and Elżbieta Chyczewska and Lech Chyczewski and Franciszek Rogowski and Jerzy Laudański},
  journal={The European respiratory journal},
  year={1995},
  volume={8 2},
  pages={291-4}
}
We wanted to investigate the diagnostic and prognostic significance of serum CYFRA 21-1, especially in predicting the risk of recurrence in patients with operable squamous cell lung cancer. Serum levels of CYFRA 21-1 were measured using an immunoradiometric assay (CIS bio) in 76 patients with squamous cell lung cancer (64 operable and 12 with unresectable tumours), 22 with other non-small-cell type (12 with adenocarcinoma and 10 with large-cell type) and 45 with nonmalignant lung diseases… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
Serum levels of CYFRA 21 - 1 were measured using an immunoradiometric assay ( CIS bio ) in 76 patients with squamous cell lung cancer ( 64 operable and 12 with unresectable tumours ) , 22 with other non - small - cell type ( 12 with adenocarcinoma and 10 with large - cell type ) and 45 with nonmalignant lung diseases .
Serum levels of CYFRA 21 - 1 were measured using an immunoradiometric assay ( CIS bio ) in 76 patients with squamous cell lung cancer ( 64 operable and 12 with unresectable tumours ) , 22 with other non - small - cell type ( 12 with adenocarcinoma and 10 with large - cell type ) and 45 with nonmalignant lung diseases .
Serum levels of CYFRA 21 - 1 were measured using an immunoradiometric assay ( CIS bio ) in 76 patients with squamous cell lung cancer ( 64 operable and 12 with unresectable tumours ) , 22 with other non - small - cell type ( 12 with adenocarcinoma and 10 with large - cell type ) and 45 with nonmalignant lung diseases .
Serum levels of CYFRA 21 - 1 were measured using an immunoradiometric assay ( CIS bio ) in 76 patients with squamous cell lung cancer ( 64 operable and 12 with unresectable tumours ) , 22 with other non - small - cell type ( 12 with adenocarcinoma and 10 with large - cell type ) and 45 with nonmalignant lung diseases .
Serum levels of CYFRA 21 - 1 were measured using an immunoradiometric assay ( CIS bio ) in 76 patients with squamous cell lung cancer ( 64 operable and 12 with unresectable tumours ) , 22 with other non - small - cell type ( 12 with adenocarcinoma and 10 with large - cell type ) and 45 with nonmalignant lung diseases .
Serum levels of CYFRA 21 - 1 were measured using an immunoradiometric assay ( CIS bio ) in 76 patients with squamous cell lung cancer ( 64 operable and 12 with unresectable tumours ) , 22 with other non - small - cell type ( 12 with adenocarcinoma and 10 with large - cell type ) and 45 with nonmalignant lung diseases .
Serum levels of CYFRA 21 - 1 were measured using an immunoradiometric assay ( CIS bio ) in 76 patients with squamous cell lung cancer ( 64 operable and 12 with unresectable tumours ) , 22 with other non - small - cell type ( 12 with adenocarcinoma and 10 with large - cell type ) and 45 with nonmalignant lung diseases .
Serum levels of CYFRA 21 - 1 were measured using an immunoradiometric assay ( CIS bio ) in 76 patients with squamous cell lung cancer ( 64 operable and 12 with unresectable tumours ) , 22 with other non - small - cell type ( 12 with adenocarcinoma and 10 with large - cell type ) and 45 with nonmalignant lung diseases .
Serum levels of CYFRA 21 - 1 were measured using an immunoradiometric assay ( CIS bio ) in 76 patients with squamous cell lung cancer ( 64 operable and 12 with unresectable tumours ) , 22 with other non - small - cell type ( 12 with adenocarcinoma and 10 with large - cell type ) and 45 with nonmalignant lung diseases .
Diagnostic and prognostic value of the new tumour marker CYFRA 21 - 1 in patients with squamous cell lung cancer .
Serum levels of CYFRA 21 - 1 were measured using an immunoradiometric assay ( CIS bio ) in 76 patients with squamous cell lung cancer ( 64 operable and 12 with unresectable tumours ) , 22 with other non - small - cell type ( 12 with adenocarcinoma and 10 with large - cell type ) and 45 with nonmalignant lung diseases .
Positive CYFRA 21 - 1 levels were observed in 33% of stage I , 52% of stage II , 76% of stage IIIa and 83% of stage IIIb patients with SqCC type .
Serum levels of CYFRA 21 - 1 were measured using an immunoradiometric assay ( CIS bio ) in 76 patients with squamous cell lung cancer ( 64 operable and 12 with unresectable tumours ) , 22 with other non - small - cell type ( 12 with adenocarcinoma and 10 with large - cell type ) and 45 with nonmalignant lung diseases .
Serum levels of CYFRA 21 - 1 were measured using an immunoradiometric assay ( CIS bio ) in 76 patients with squamous cell lung cancer ( 64 operable and 12 with unresectable tumours ) , 22 with other non - small - cell type ( 12 with adenocarcinoma and 10 with large - cell type ) and 45 with nonmalignant lung diseases .
All Topics